Ashley Matney
Internal Medicine · Edmonton, KYNPI 1558654806
Payments from drug & device makers
Across 158 payments — averaging $16.48 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Pfizer$329
- Amgen$264
- Boehringer Ingelheim$247
- Lilly USA, LLC$215
- Novo Nordisk$185
- Merck$172
- plus $1K from 19 others
What the payments were for
- Food & beverage$2,605100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Pfizer | 23 | $329 |
| Amgen | 13 | $264 |
| Boehringer Ingelheim | 17 | $247 |
| Lilly USA, LLC | 15 | $215 |
| Novo Nordisk | 12 | $185 |
| Merck | 12 | $172 |
| Amarin Pharma, Inc. | 10 | $157 |
| Dexcom, Inc. | 4 | $152 |
| Merz North America, Inc. | 1 | $150 |
| AstraZeneca | 10 | $139 |
| Johnson & Johnson | 7 | $100 |
| AbbVie | 6 | $93 |
| Takeda Pharmaceuticals U.S.A., Inc. | 8 | $90 |
| Bayer | 6 | $88 |
| Kowa Pharmaceuticals America, Inc. | 3 | $66 |
| Biohaven Pharmaceuticals, Inc. | 2 | $33 |
| Sanofi Pasteur Inc. | 1 | $18 |
| Mylan Specialty L.p. | 1 | $18 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $15 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $14 |
| Mannkind Corporation | 1 | $12 |
| Novartis | 1 | $12 |
| Eisai Inc. | 1 | $12 |
| Arbor Pharmaceuticals, Inc. | 1 | $12 |
| Esperion Therapeutics, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$2,605 in reported general payments places this provider in the 80th percentile of 1,284 internal medicine providers in Kentucky.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 66 | $63,468 |
| JanuviaSitagliptin Phosphate | 70 | $49,046 |
| OzempicSemaglutide | 41 | $42,704 |
| JardianceEmpagliflozin | 32 | $42,105 |
| MounjaroTirzepatide | 27 | $32,483 |
| VraylarCariprazine Hcl | 12 | $17,079 |
| XareltoRivaroxaban | 16 | $15,067 |
| TrulicityDulaglutide | 14 | $12,448 |
| Breo ElliptaFluticasone/Vilanterol | 14 | $8,772 |
| SymbicortBudesonide/Formoterol Fumarate | 24 | $6,063 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 11 | $5,632 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 102 | $3,934 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 30 | $3,858 |
| Humalog Kwikpen U-100Insulin Lispro | 13 | $3,696 |
| Levothyroxine Sodium | 193 | $2,004 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $329 | $63,46866 claims |
| MerckJanuvia | $172 | $49,04670 claims |
| Lilly USA, LLCMounjaro, Trulicity | $215 | $44,93141 claims |
| Novo NordiskOzempic | $185 | $42,70441 claims |
| Boehringer IngelheimJardiance | $247 | $42,10532 claims |
| AbbVieVraylar | $93 | $17,07912 claims |
| Johnson & JohnsonXarelto | $100 | $15,06716 claims |
| AstraZenecaSymbicort | $139 | $6,06324 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 1,284 internal medicine providers in Kentucky.
Other internal medicine in Edmonton
- Mark AdamsLondon$15.4M
- Matthew WenkerErlanger$12.8M
- Jason ChesneyLouisville$6.3M
- Neil FarrisLexington$3M
- David JohnsonOwensboro$787K
- Hollis ClarkMurray$780K
- Fares KhaterWhitesburg$412K
- Christopher PhillipsPaducah$315K
- Cynthia Bowman-StroudPaducah$234K
- Bernard BuchananOwensboro$224K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.